Genentech is set to reintroduce Susvimo for patients with wet age-related macular degeneration nearly 2 years after it voluntarily recalled the ocular implant, according to a press release.
The FDA approved a post-approval supplement to the biologics license application for Susvimo (ranibizumab injection 100 mg/mL). The implant, which continuously delivers a customized formulation of ranibizumab through the port delivery platform, is inserted during a one-time outpatient procedure and refilled every 6 months with a specially designed needle.
Susvimo was initially approved in 2021, but Genentech